S-1/A: Farlong Holding IPO Faces Going Concern Doubts Amid Losses

Farlong Holding Corporation, a health and wellness company, is pursuing an initial public offering despite recurring losses and substantial doubt about its ability to continue as a going concern.

Summary

• Farlong Holding Corporation is a science-driven healthcare and wellness company specializing in proprietary herbal dietary supplements and the DirecTCM platform.
• The company is seeking to raise approximately $14.3 million (or $16.4 million if the over-allotment option is fully exercised) through an initial public offering of 4,000,000 shares at an estimated price of $4.00 per share.
• Farlong has experienced recurring net losses, reporting $1,900,073 for the nine months ended June 30, 2025, an increase from $1,494,332 for the same period in 2024.
• The company also had negative operating cash flows of $1,705,308 for the nine months ended June 30, 2025, and an accumulated deficit of $5,984,259 as of that date.
• Management has identified substantial doubt about the company's ability to continue as a going concern due to these financial conditions.
• Revenue for the nine months ended June 30, 2025, increased by 15.07% to $557,104, driven by a strategic shift to higher-potential BioPrecision formulations and new OEM customer relationships.
• Gross profit decreased by 16.44% to $310,853 for the nine months ended June 30, 2025, with gross margin falling to 55.80% from 76.84% due to lower margins on BioPrecision products.
• Selling expenses surged by 266.16% to $365,154, primarily due to initial marketing efforts on TikTok for the new BioPrecision product line.
• Research and development expenses increased to $106,375 for the nine months ended June 30, 2025, from nil in the prior year, mainly for preclinical trials with City of Hope.
• The DirecTCM platform, launched in May 2025, had 30,000 pre-registered healthcare providers but only 75 active users as of June 30, 2025, generating limited subscription revenue of $376.
• The company relies heavily on a few key customers and vendors, with ZenLife accounting for 27% of revenue and Kunming Aoqun for 49% of purchases for the nine months ended June 30, 2025.
• Significant related-party transactions include multiple loans from Karin Mei Huang, the beneficial owner of 90.9% of voting power, totaling $2.6 million as of June 30, 2025, with an additional $2 million loan on September 26, 2025.

Sentiment

Score: 3

Explanation: The company faces significant financial challenges, including recurring losses, negative cash flow, and substantial doubt about its ability to continue as a going concern. While revenue is growing and new products are launching, profitability is declining, and there's heavy reliance on related-party financing. The IPO is a critical capital raise, but the underlying financial health is weak.

Positives

• Revenue increased by 15.07% to $557,104 for the nine months ended June 30, 2025, driven by strategic product line restructuring and new OEM customer relationships.
• Average revenue per wholesale customer increased by 21.84% to approximately $6,000, and per retail customer by 91.19% to approximately $2,000, indicating higher value per customer.
• The BioPrecision formulation product line, launched in July 2024, generated approximately $0.3 million in revenue for the nine months ended June 30, 2025, showing strong initial demand.
• The DirecTCM platform, launched in May 2025, has accumulated 30,000 pre-registered healthcare providers, offering a significant potential customer base.
• The company is actively investing in R&D, including preclinical research studies with City of Hope for potential anti-cancer and anti-diabetes applications of botanical ingredients.
• Farlong has an experienced management team with over two decades of experience in strategic planning, market development, financial management, and corporate governance.
• The company holds 13 active registered trademarks and relies on trade secrets and proprietary knowledge in formulation-based product development.

Negatives

• The company has experienced recurring net losses, with a net loss of $1,900,073 for the nine months ended June 30, 2025, and $1,955,962 for the fiscal year ended September 30, 2024.
• Negative cash flows from operating activities persist, amounting to $1,705,308 for the nine months ended June 30, 2025, and $1,918,192 for the fiscal year ended September 30, 2024.
• An accumulated deficit of $5,984,259 as of June 30, 2025, raises substantial doubt about the company's ability to continue as a going concern.
• Gross profit decreased by 16.44% and gross margin declined to 55.80% for the nine months ended June 30, 2025, primarily due to the lower gross margin of the new BioPrecision product line (30.88%).
• Selling expenses increased significantly by 266.16% due to initial marketing efforts, indicating high customer acquisition costs for new product lines.
• The DirecTCM platform, despite 30,000 pre-registered providers, had only 75 active users (0.25%) and generated immaterial subscription revenue ($376) in its initial months.
• Clinical studies sponsored by the company have not demonstrated statistically significant outcomes, which may diminish consumer confidence and competitive advantage.
• The company has identified material weaknesses in internal control over financial reporting, including a lack of formal risk assessment policies and IT-related deficiencies.
• Heavy reliance on a small number of customers and vendors poses significant concentration risk; loss of any material party could adversely affect operations.
• All supplement products are produced by third-party contract manufacturers located in China, making the company highly vulnerable to U.S. tariffs, trade disputes, and supply chain disruptions.
• Two U.S. process patents covering key extraction methods for legacy products have expired, removing statutory patent protection.

Risks

• Substantial doubt about the ability to continue as a going concern due to recurring losses and negative cash flows.
• Need for additional capital, which may not be available on commercially acceptable terms, if at all, leading to potential dilution or inability to execute business plans.
• Operating results may vary considerably in the future, making forecasting challenging and potentially causing results to fall short of expectations.
• Failure to maintain high-quality standards for products and services could harm business and reputation, leading to recalls or customer loss.
• Significant revenue and purchases are concentrated with a small number of customers and vendors, posing a risk if these relationships are lost or disrupted.
• Customer demand is difficult to forecast accurately, potentially leading to inability to match planning and spending decisions.
• Reliance on Amazon and TikTok for a significant portion of revenue (15% and 19% respectively for 9M 2025) exposes the business to platform policy changes or restrictions.
• Increases in ingredient costs, long lead times, and supply shortages could disrupt the supply chain and negatively impact financial results.
• Allocation of limited resources to particular products or services may lead to failure to capitalize on more profitable opportunities.
• Risk of inventory spoliation due to definitive shelf-lives, potentially leading to significant write-offs.
• Failure to renew current leases or locate desirable alternatives for facilities could materially and adversely affect business operations.
• Future need for licenses for third-party technology may be unavailable or offered on commercially unreasonable terms, increasing costs or causing adverse effects.
• High costs and uncertainty of litigation may prevent enforcement of intellectual property rights against third parties.
• Struggles to partner for technological advancements and new products/services could hinder competitiveness.
• Use of open-source software could subject proprietary software to general release, hinder product sales, and expose the company to litigation.
• Exposure to risks associated with credit card and other online payment chargebacks and fraud.
• Risks associated with the seven-day return policy and limited warranty if actual returns or claims exceed estimates.
• Inherent risks in clinical studies, particularly as current study results have not demonstrated statistical significance, impacting marketing and consumer confidence.
• Dependence on brands (Dr. Herbal Well, Best Doctor Formula) means any failure to maintain, protect, or enhance them could adversely affect the business.
• Sourcing ingredients from foreign suppliers, primarily China, exposes the company to international trade risks, including tariffs, trade disputes, and supply chain disruptions.
• Reliance on distributors and health professionals for a substantial portion of sales, over whom the company has limited control, could impact revenue if relationships deteriorate or compliance fails.
• Reliance on independent third-party transportation providers for all product shipments, subject to increased costs and potential delivery delays.
• Insurance may not fully cover all operational risks, and changes in cost or availability could increase expenses or decrease coverage.
• Disruptions in data and information systems, including cybersecurity risks, could harm reputation and business operations.
• Third parties may claim infringement of their intellectual property rights, leading to significant legal expenses and prevention from promoting products.
• Inability to protect the confidentiality of trade secrets and know-how could harm business and competitive position.
• Inadequate protection of trademarks and trade names may hinder name recognition and adversely affect business.
• Business is subject to risks from natural and manmade catastrophic events.
• Failure to attract or retain key personnel, including executive officers, senior management, and key employees, could materially and adversely affect operations and growth.
• Cybersecurity risks, including a recent ransomware incident at the underwriter, could adversely affect business and disrupt operations.
• Reliance on third parties for computing, storage, processing, and related services means any disruption could negatively impact business.
• Future acquisitions may have an adverse effect on the ability to manage business and could cause dilution to stockholders.
• Competition in the highly competitive herbal supplement industry from existing and new entrants may decrease net revenue.
• Global economic conditions could materially and adversely affect business, financial condition, results of operations, and growth.
• Subject to numerous laws and regulations applicable to the herbal supplement industry, with potential for fines, recalls, or halting production if violated.
• Changes in FDA and other regulatory agency policies, or disagreements over product classifications, could delay or increase costs.
• Marketing activities are subject to strict governmental regulation (FTC Act, DSHEA), which may limit ability to market or promote products.
• Failure to comply with federal, state, and foreign laws and regulations relating to privacy, data protection, and consumer protection could result in significant liability and harm reputation.
• Potential for allegations, harassment, or other detrimental conduct by third parties, harming reputation and causing loss of market share.
• No public market for common stock prior to this offering, and inability to resell at or above IPO price.
• Market price of common stock may be volatile or decline regardless of operating performance.
• Immediate and substantial dilution in the net tangible book value of common stock purchased in this offering ($3.73 per share).
• Failure to implement and maintain effective internal controls or remediate identified material weaknesses could lead to inaccurate financial reporting or fraud.
• Substantial increased costs as a result of being a public company, including compliance with Sarbanes-Oxley Act.
• Inability to continue to satisfy Nasdaq listing requirements could lead to delisting.
• Management has broad discretion over the use of IPO funds, which may not enhance results or stock price.
• Controlled company status allows reliance on corporate governance exemptions, potentially reducing protections for public stockholders.
• Anti-takeover provisions in Articles of Incorporation and Bylaws, as well as Nevada law, might discourage, delay, or prevent a change in control.
• The sale of a significant number of shares after lock-up expiration may cause the market price to drop significantly.

Future Outlook

The company intends to expand its DirecTCM platform and product offerings, invest further in technology and R&D, and grow its business through wider e-commerce presence and potential international expansion. It plans to increase investment in marketing and build a larger sales team. The company also aims to continue developing BioPrecision formulations and fund ongoing studies investigating anti-cancer and anti-diabetes applications. However, the ability to achieve profitable operations is dependent on increasing revenue to support its cost structure, and there is substantial doubt about its ability to continue as a going concern.

Management Comments

• Management has determined that recurring losses from operations and negative cash flows from operating activities raise substantial doubt about our ability to continue as a going concern.
• We believe that these supplier relationships provide us reliable access to inventory, volume purchasing benefits, and the ability to deliver a diverse product offering cost-effectively.
• The BioPrecision formulation product line has resonated strongly with both healthcare providers and consumers, validating our focus on premium, science-backed supplements.
• We are dedicated to providing authentic and personalized health solutions that meet a high standard of quality and consumer trust.
• Our regulatory objective is limited to marketing our formulations in the United States as dietary supplements, for which FDA approval is neither required nor available.
• We prioritize integrating centuries-old herbal wisdom with modern clinical validation. This framework of combining traditional knowledge + modern R&D fuels product innovation and competitive advantage.

Industry Context

The global dietary supplement market is valued at $74.3 billion in 2024 and is projected to reach $170.1 billion by 2034, growing at a CAGR of 9.5%. The holistic herbal supplement market is also expanding, from $216 billion in 2022 to an expected $421 billion by 2032 (CAGR of 6.87%). Farlong operates in this growing market, focusing on plant-based, natural, and clean-label products, aligning with consumer preferences for healthier options. However, the industry is highly competitive with many larger, more resourced competitors. The company's reliance on Chinese manufacturers exposes it to U.S.-China trade tensions and tariffs, which could impact costs and competitiveness.

Comparison to Industry Standards

• The company's gross margin of 55.80% for the nine months ended June 30, 2025, is lower than the 76.84% in the prior period, indicating potential pricing pressure or higher costs for its new BioPrecision line, which had a gross margin of 30.88%. This suggests the new product line is currently less profitable than legacy dietary supplements (82.51% gross margin).
• The company faces competition from established players like Throne HealthTech, Nestle Health Science, and Metagenics in the nutritional supplement market, and Fullscript in supplement online ordering. These competitors often have greater financial, technological, and marketing resources.
• While the company aims to differentiate through science-based, personalized wellness solutions and its DirecTCM platform, the low active user rate (0.25% of pre-registered providers) on DirecTCM suggests it has not yet achieved significant market penetration or competitive advantage through this platform.
• The company's preclinical studies have not demonstrated statistically significant outcomes, which is a notable difference from the rigorous, statistically powered clinical trials often conducted by larger pharmaceutical or nutraceutical companies to substantiate efficacy claims.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit was filed against Longstar on June 20, 2024, by a former employee alleging $1,222,000 in unpaid compensation from 2016 to 2023. Longstar's legal counsel believes the likelihood of liability is remote, and no loss contingency has been recorded.

Related Party Transactions

• Long-term loans from Karin Mei Huang (beneficial owner of 90.9% voting power): $1,000,000 loan dated September 15, 2024 (9.5% interest, maturing September 15, 2029), $1,600,000 loan dated March 25, 2025 (9.5% interest, maturing March 25, 2030), and $2,000,000 loan dated September 26, 2025 (9.5% interest, maturing September 26, 2030).
• Accrued loan interest to Karin Mei Huang was $67,593 as of June 30, 2025.
• Rent deposit of $19,500 and rent expenses of $117,000 (9 months ended June 30, 2025) paid to Longstar Healthpro Manufacturing Inc., which is majority owned by Xinjiang Lixing Investment and Management Co., a former stockholder of Longstar and owned by Lihua Zeng (family member of Lipin Zeng, Karin Mei Huang's husband).
• Purchases from Kunming Aoqun Bio-Tech Co., Ltd. amounted to $131,148 (9 months ended June 30, 2025), with accounts payable of $781,668 as of June 30, 2025. Kunming Aoqun is a related party as Ms. Lihua Zeng serves as its director.
• Purchases from Yunnan Panlong Yunhai Pharmaceutical Co., Ltd. (related party through Lihua Zeng) with accounts payable of $60,441 as of June 30, 2025. An additional $23,390 in inventories was purchased from Yunnan Panlong Yunhai Pharmaceutical Trading Co., Ltd. (a subsidiary of Yunnan Panlong) on July 28, 2025.

Stakeholder Impact

• Shareholders: Will experience immediate and substantial dilution of $3.73 per share from the IPO. Existing shareholders (KML Family Trust and KMA Trust) will retain 90.9% voting power, making the company a controlled company, which could limit the influence of public shareholders on corporate governance.
• Employees: The company plans to expand its workforce, including hiring eight field sales representatives, and offers a 401(k) plan. However, the 'going concern' doubt poses a risk to job security and long-term stability.
• Customers: The strategic shift to BioPrecision formulations and expansion of sales channels (DirecTCM, e-commerce) aim to provide more personalized health solutions. However, the low active user rate on DirecTCM and potential quality control issues or supply chain disruptions could impact customer satisfaction.
• Suppliers: Heavy reliance on a few key suppliers, particularly those in China, exposes them to risks related to trade disputes and tariffs, which could affect their business with Farlong.
• Creditors: The company's recurring losses, negative cash flows, and 'going concern' doubt increase credit risk. Significant related-party loans from Karin Mei Huang indicate reliance on internal financing to sustain operations.

Next Steps

• Complete the initial public offering and list common stock on the Nasdaq Capital Market under the symbol AFA.
• Allocate net proceeds from the IPO for general corporate purposes, R&D, marketing, infrastructure upgrades, and international expansion.
• Continue expanding services on the DirecTCM platform and promoting BioPrecision products.
• Invest further in technology and R&D, including ongoing preclinical research studies with City of Hope.
• Increase investment in marketing and build a larger sales team to expand customer base and average revenue per customer.
• Implement remedial measures for identified material weaknesses in internal control over financial reporting, including hiring qualified accounting personnel and implementing training programs.
• Maintain compliance with Nasdaq listing requirements and prepare for Sarbanes-Oxley Act Section 404 reporting starting with the fiscal year ending September 30, 2026.
• The Audit Committee will review and approve related party transactions moving forward.

Key Dates

Recommendation

The company's financial statements explicitly state 'substantial doubt about our ability to continue as a going concern' due to recurring losses and negative cash flows. The net loss increased significantly, gross margins declined, and there's heavy reliance on related-party debt. While the IPO aims to raise capital, the underlying operational and financial weaknesses, coupled with high dilution for new investors and significant concentration risks, make this a highly speculative investment with a high probability of capital loss. A seasoned investor would likely avoid or sell given the severe going concern warning.

Keywords

Herbal Supplements, Dietary Supplements, Traditional Chinese Medicine, TCM, Health and Wellness, BioPrecision, DirecTCM, IPO, SEC Filing, Nasdaq, Nutraceuticals, Contract Manufacturing, E-commerce, Risk Factors, Going Concern